HUMAW vs. ATNFW, SXTPW, DRTSW, APLMW, ARTLW, BCDAW, BCTXW, CDIOW, CTCXW, and SAVAW
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), Artelo Biosciences (ARTLW), BioCardia (BCDAW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), and Cassava Sciences (SAVAW). These companies are all part of the "biotechnology" industry.
Humacyte (NASDAQ:HUMAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
In the previous week, Humacyte had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Humacyte and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.87 beat Humacyte's score of 1.43 indicating that 180 Life Sciences is being referred to more favorably in the news media.
Humacyte and 180 Life Sciences both received 0 outperform votes by MarketBeat users.
Summary
Humacyte and 180 Life Sciences tied by winning 1 of the 2 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMAW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUMAW vs. The Competition
Humacyte Competitors List
Related Companies and Tools
